Research Article

Association of *Helicobacter pylori* Infection with Glycemic Control in Patients with Diabetes: A Meta-Analysis

Chika Horikawa,^{1,2,3} Satoru Kodama,^{2,4} Kazuya Fujihara,^{2,3,4} Yoko Yachi,² Shiro Tanaka,⁵ Akiko Suzuki,² Osamu Hanyu,² Hitoshi Shimano,³ and Hirohito Sone²

¹ Department of Health and Nutrition, Faculty of Human Life Studies, University of Niigata Prefecture, Niigata, Japan

² Department of Internal Medicine, Faculty of Medicine, Niigata University, 1-754 Asahimachi, Niigata 951-8510, Japan

³ Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan

⁴ Department of Health Management Center, Mito Kyodo General Hospital, Ibaraki, Japan

⁵ Department of Clinical Trial, Design & Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan

Correspondence should be addressed to Hirohito Sone; sone@med.niigata-u.ac.jp

Received 13 January 2014; Revised 24 April 2014; Accepted 24 April 2014; Published 8 May 2014

Academic Editor: Norman Cameron

Copyright © 2014 Chika Horikawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess the association between *Helicobacter pylori* (HP) infection and glycemic control in patients with diabetes through a meta-analytic approach. **Research Design and Methods.** Electronic literature searches were conducted for cross-sectional studies that examined the hemoglobin A1c (A1C) level by whether patients with diabetes were or were not carriers of HP. Mean differences in A1C between groups with and without HP infection were pooled with a random-effects model. **Results.** Thirteen eligible studies were included in this meta-analysis. Overall, the HP carriers did not have significantly higher A1C levels compared with HP noncarriers (mean difference (95% CI), 0.19% (−0.18 to 0.46), $P = 0.16$). When the analysis was limited to studies targeting patients with type 1 diabetes, there was also no significant difference in A1C (0.69% (−0.31 to 1.68), $P = 0.18$). **Conclusions.** There was insufficient evidence that HP infection worsened glycemic control in patients with diabetes.

1. Introduction

Glycemic control is essential in the management of diabetes to prevent diabetic complications as well as their progression, if present [1]. Among various factors that influence the management of the blood glucose level, chronic infections such as periodontal disease [2] or tuberculosis [3] are major causes of worsening of glycemic control or of difficulty in glycemic control.

Helicobacter pylori (HP) is a major human bacterial pathogen, the chronic infection of which causes a number of upper gastrointestinal conditions such as chronic gastritis, peptic ulcer disease, gastric malignancy, and gastric mucosa associated lymphoid tissue lymphoma [4]. Moreover, a recent meta-analysis showed that HP infection is 1.3-fold more prevalent in persons with diabetes than in those without diabetes [5]. However, results are inconsistent among studies of the association between chronic HP infection and poor

glycemic control in patients with diabetes. The aim of this meta-analysis is to compare glycemic control in patients with diabetes according to the presence or absence of HP.

2. Materials and Methods

An electronic literature search was conducted using the search engine Proquest Dialog, which made it possible to search several databases simultaneously. We chose the following databases related to medicine: Biosis (1926 to March 26, 2014), MEDLINE (1950 to March 26, 2014), Embase (1947 to March 26, 2014), PASCAL (1973 to March 26, 2014), and SciSearch (1974 to March 26, 2014). The search equation was produced by combining keywords related to HP and diabetes using the Boolean operator “AND” (Table 1).

Studies were included if they targeted patients with diabetes and provided data on the mean hemoglobin A1c

TABLE 1: Study keywords in this meta-analysis.

S1 [Related to diabetes mellitus]
Thesaurus terms
EMBASE (“insulin dependent diabetes mellitus” [NoExp] OR “juvenile diabetes mellitus” [NoExp] OR “diabetic patient” [NoExp] OR “diabetes mellitus” [NoExp] OR “maturity onset diabetes mellitus” [NoExp] OR “non insulin dependent diabetes mellitus” [NoExp])
MEDLINE (“Diabetes Mellitus” [NoExp] OR “Diabetes Mellitus, Type 2” [NoExp] OR “Diabetes Mellitus, Type 1” [NoExp])
text words
(“diabetes” OR “NIDDM” OR “IDDM” OR “diabetic”)
S2 [Related to Helicobacter Pylori]
Thesaurus terms
EMBASE (“Helicobacter pylori” [Exp] OR “Helicobacter infection”)
MEDLINE (“Helicobacter pylori”) [Exp]
Test word
“pylori”
S3 1 AND 2

[Exp] indicates automatic inclusion of all of the narrower terms under the specified descriptor in the thesaurus hierarchy.

[NoExp] exclusively searches for the specified descriptor.

asterisk (*) indicates an inflection of the corresponding word.

(A1C) level and its corresponding standard error according to whether the patients carried HP. Two of our investigators (Chika Horikawa and Satoru Kodama) independently abstracted these data. Discrepancies were resolved by a third investigator (Hirohito Sone).

Mean differences in A1C between groups with and without HP infection were pooled with a random-effects model using the DerSimonian and Laird method [6]. The extent of between-study heterogeneity was assessed by I-squared statistics [7]. Analyses were repeated for subgroups within which the same study characteristics were shared. Publication bias was statistically assessed by two formal methods: Begg’s rank correlation and Egger’s regression tests [8, 9]. Two-sided $P < 0.05$ was considered statistically significant with the exception of the test for publication bias where $P < 0.10$ was used [10]. All analyses were conducted with Stata statistical software (version 11, StataCorp, College Station, TX, USA).

3. Results

3.1. Literature Search and Study Characteristics. Figure 1 shows details of the literature search. Of the 1976 citations retrieved from the systematic literature searches, 14 eligible studies [11–24] were obtained.

Characteristics of the 14 selected studies [11–24] comprising 1781 diabetic participants (range, 63–333 participants) and 990 HP-infected participants (range, 11–187 participants) are shown in Table 2. Proportion of men and mean age of study participants ranged from 30.8% to 58.9% and from 11.3 years to 66.3 years, respectively. Seven studies [11–16, 24] included only type 2 diabetes mellitus patients, 5 [19–23] included only type 1 diabetes mellitus patients, and 2 [17, 18] included both type 1 and type 2 diabetes mellitus patients. Four studies [17, 19–21] were conducted in Western countries and 10 studies [11–16, 18, 22–24] took place in non-Western countries. Five of the 14 studies [11–15] used a biopsy for

identifying HP infection and the remaining 9 studies [16–24] used other methods such as measurement of HP-specific immunoglobulin G using an enzyme immunoassay and the (13C) urea breath test. Mean duration of diabetes ranged from 2.9 to 16.1 years.

3.2. Overall Estimate of Differences in A1C between Diabetic Patients with and without HP Infection. A total of 14 datasets were included in this meta-analysis. Figure 2 shows a forest plot of mean differences in A1C with their corresponding 95% confidence intervals (CIs) for patients with diabetes with HP infection versus those without HP infection. Overall, compared with HP carriers, the HP carriers did not have significantly higher A1C levels (mean difference (95% CI), 0.19% (−0.08 to 0.46), $P = 0.16$). Publication bias was not statistically detected by Egger’s test ($P = 0.45$) and Begg’s test ($P = 0.62$).

3.3. Stratified Analysis. Stratified and metaregression analyses across a number of key study characteristics to explore the origin of the heterogeneity and the influence of the characteristics on study results are shown in Table 3.

When limiting the analysis to the 5 studies that exclusively targeted type 1 diabetes, also no significant difference in A1C was observed (0.69% (−0.31 to 1.68), $P = 0.18$). Including the type of diabetes, other items such as duration of diabetes, geographic region, and methodological features for determination of HP infection did not significantly influence study results.

4. Discussion

The current meta-analysis produced insufficient evidence that chronic infection with HP was associated with poor glycemic control in patients with diabetes. This finding

FIGURE 1: Flow chart of meta-analysis. HP: *Helicobacter pylori*; A1C: hemoglobin A1C. FIGURE 2: Forest plot of mean differences with corresponding 95% confidence intervals (CIs) in hemoglobin A1C (A1C) for patients with diabetes with *Helicobacter pylori* infection versus those with *Helicobacter pylori* noninfection. Size of squares reflects the statistical weight of each study. Pooled mean difference in A1C is indicated by an unshaded diamond.

TABLE 2: Characteristics of studies included in the meta-analysis.

Author	Year	Country	Type of diabetes	Men (%)	Mean age (year)	Duration of diabetes (year)	Mean BMI	Number of participants		Mean HbA1c value (%)		Method for identifying HP infection
								HP infected	HP non-infected	HP infected	HP non-infected	
Vafaieimanes et al. [24]	2014	Iran	T2DM	36.0	52.5	7.4	29.0	139	82	8.11	8.08	HP-specific IgG using EIA
Senmaru et al. [16]	2013	Japan	T2DM	58.9	66.3	15.1	22.8	187	146	7.4	7.3	HP-specific IgG using EIA
El-Eshawy et al. [22]	2011	Egypt	T1DM	44.5	19.4	7.3	NA	128	34	8.3	6.8	HP-specific IgA and IgG using EIA
Tanriverdi [15]	2011	Turkey	T2DM	52.7	55.4	2.9	28.2	53	40	6.9	6.1	Biopsy
Fernandini-Paredes et al. [11]	2008	Chile	T2DM	46.7	52.8	8.2	NA	49	26	7.7	7.3	[13C]urea breath test and biopsy
Demir et al. [12]	2008	Turkey	T2DM	32.2	52.0	6.1	NA	87	54	7.9	8.7	Biopsy
Hamed et al. [18]	2008	Egypt	T1DM and T2DM	48.8	47.5	9.2	28.8	68	12	8.1	8.3	HP-specific IgG using EIA
Gulcelik et al. [13]	2005	Turkey	T2DM	30.8	51.9	6.9	26.0	59	19	8.2	7.9	Biopsy
Candelli et al. [19]	2003	Italy	T1DM	54.5	14.8	6.6	20.9	34	87	8.3	8.2	[13C]urea breath test
Colombo et al. [20]	2002	Italy	T1DM	52.9	12.0	5.5	NA	41	97	7.8	8.6	HP-specific IgA and IgG using EIA
Ko et al. [14]	2001	China	T2DM	46.0	49.9	6.2	NA	32	31	8.1	8.4	Biopsy
Arsilan et al. [23]	2000	Turkey	T1DM	40.9	12.6	10.7	NA	49	39	11.1	10.2	HP-specific IgG using EIA
Begue et al. [21]	1999	USA	T1DM	50.7	11.3	3.6	20.0	11	60	14.9	11.8	HP-specific IgG using EIA
de Luis et al. [17]	1998	Spain	T1DM and T2DM	50.4	60.2	16.1	28.8	53	74	7.1	7.2	HP-specific IgG using EIA

Abbreviations: HP: *Helicobacter pylori*; EIA: enzyme immunoassay; IgA: immunoglobulin A; IgG: immunoglobulin G; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus.

TABLE 3: Stratified analyses of differences between those with *Helicobacter pylori* (HP) infection versus those without HP infection in hemoglobin A1C level with 95% confidence interval according to key study characteristics.

Variable	Number of data	Mean difference (95% CI), %	Q statistics	I^2 (%)	P-value for heterogeneity	Meta-regression
Total	14	0.19 (−0.18 to 0.46)	53.6	75.8%	<0.001	—
Geographic region						
Western	4	0.08 (−0.72 to 0.88)	14.5	79.3%	0.002	Referent
Non-western	10	0.28 (−0.01 to 0.57)	36.6	75.3%	<0.001	0.47
Type of diabetes						
Type 1 diabetes mellitus only	5	0.69 (−0.31 to 1.68)	28.8	86.1%	<0.001	Referent
Type 2 diabetes mellitus was included	9	0.12 (−0.13 to 0.37)	24.8	67.8%	0.002	0.38
Duration of diabetes						
≥8 years	6	0.11 (−0.19 to 0.41)	18.2	78.0%	<0.001	Referent
<8 years	8	0.30 (−0.24 to 0.84)	34.9	77.1%	<0.001	0.73
Method for determination of HP infection						
Biopsy	5	0.40 (0.22 to 0.58)	5.3	24.8%	0.26	Referent
Other methods	9	0.14 (−0.20 to 0.48)	34.4	76.7%	<0.001	0.83

seemed contradictory to the biological finding that HP infection stimulates inflammatory responses leading to insulin resistance and persistent hyperglycemia [25] by producing proinflammatory cytokines such as C-reactive protein and interleukin-6 [18, 26]. The speculation for this contradiction is that stimulus by the HP infection of an inflammatory response might be insufficient to worsen glycemic control.

Other speculations may be that (1) chronic hyperglycemia caused by HP infection could have been compensated by increasing doses of antihyperglycemic drugs [21] and (2) the potentially worsening glycemic control might be counterbalanced by “successful” weight control as a result of chronic gastritis and lack of appetite. However, more information on details of treatments, including antihyperglycemic medications, or nutrition surveys of patients with and without HP infection, is necessary to elucidate these speculations.

Major limitation of this meta-analysis is that it did not consider various characteristics other than HP infection that would have influenced glycemic control, such as status of treatment, age, gender, obesity indicators, or smoking status. The difference in A1C levels between patients with and without HP infection might have been attributed more strongly to characteristics for which no included studies matched rather than to HP infection itself. Therefore, this study might have failed to investigate the direct association between HP infection and glycemic control. An additional limitation was that potential publication bias could not be ruled out because of the strong evidence that infection could elevate the blood glucose level even if it was not statistically detected.

To more directly examine the association between HP infection and glycemic control would be to investigate the effect of HP eradication on glycemic control. Unfortunately, we could not conduct a meta-analysis of studies that investigated A1C levels before and after HP eradication because of the insufficient number of such eligible studies [27–31]. Although the results were inconsistent among studies, most

studies [27–30] did not indicate the effectiveness of HP eradication on glycemic control with one exception [31]. Nevertheless, further studies would need to investigate the effect of eradication on glycemic control to clarify whether HP infection influences glycemic control.

5. Conclusions

This meta-analysis produced insufficient evidence that chronic infection with HP worsened glycemic control in patients with diabetes. More studies are needed to investigate the effect of HP eradication on glycemic control to prove the influence of HP infection on glycemic control.

Disclosure Summary

The authors declare that there is no duality of interest associated with this paper. All authors researched data, contributed to the discussion, and wrote and edited the paper. Dr. Sone had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interests

No potential conflict of interests relevant to this paper was reported.

Funding

Chika Horikawa is a recipient of a Grant-in-Aid from Honjo International Scholarship Foundation (HISF), Japan, and University of Tsukuba Research Infrastructure Support Program, Japan. Hirohito Sone is a recipient of a Grant-in-Aid for Scientific Research (#20300227) from the Japan Society for the Promotion of Science (JSPS). This work is also

financially supported by the Ministry of Health, Labor and Welfare, Japan. The sponsors had no influence over the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the paper.

Acknowledgments

Thanks are extended to Ms. Mami Haga and Ms. Natsuko Tada, Niigata University, for their excellent secretarial assistance.

References

- [1] American Diabetes Association, "Standards of medical care in diabetes—2013," *Diabetes Care*, vol. 36, pp. S11–S66, 2013.
- [2] G. W. Taylor and W. S. Borgnakke, "Periodontal disease: associations with diabetes, glycemic control and complications," *Oral Diseases*, vol. 14, no. 3, pp. 191–203, 2008.
- [3] T. Sen, S. R. Joshi, and Z. F. Udwadia, "Tuberculosis and diabetes mellitus: merging epidemics," *Journal of Association of Physicians of India*, vol. 57, no. 5, pp. 399–404, 2009.
- [4] W. D. Chey and B. C. Y. Wong, "American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection," *American Journal of Gastroenterology*, vol. 102, no. 8, pp. 1808–1825, 2007.
- [5] X. Zhou, C. Zhang, J. Wu et al., "Association between *Helicobacter pylori* infection and diabetes mellitus: a meta-analysis of observational studies," *Diabetes Research and Clinical Practice*, vol. 99, pp. 200–208, 2013.
- [6] R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," *Controlled Clinical Trials*, vol. 7, no. 3, pp. 177–188, 1986.
- [7] J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis," *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.
- [8] C. B. Begg and M. Mazumdar, "Operating characteristics of a rank correlation test for publication bias," *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1994.
- [9] M. Egger, G. Davey Smith, M. Schneider et al., "Bias in meta-analysis detected by a simple, graphical test," *British Medical Journal*, vol. 315, pp. 629–634, 1997.
- [10] J. A. C. Sterne, D. Gavaghan, and M. Egger, "Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature," *Journal of Clinical Epidemiology*, vol. 53, no. 11, pp. 1119–1129, 2000.
- [11] G. G. Fernandini-Paredes, E. Mezones-Holguin, R. Vargas-Gonzales, E. Pozo-Briceño, and A. J. Rodriguez-Morales, "In patients with type 2 diabetes mellitus, are glycosylated hemoglobin levels higher for those with *Helicobacter pylori* infection than those without infection?" *Clinical Infectious Diseases*, vol. 47, no. 1, pp. 144–146, 2008.
- [12] M. Demir, H. S. Gokturk, N. A. Ozturk, M. Kulaksizoglu, E. Serin, and U. Yilmaz, "*Helicobacter pylori* prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications," *Digestive Diseases and Sciences*, vol. 53, no. 10, pp. 2646–2649, 2008.
- [13] N. E. Gulcelik, E. Kaya, B. Demirbas et al., "*Helicobacter pylori* prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy," *Journal of Endocrinological Investigation*, vol. 28, no. 3, pp. 214–217, 2005.
- [14] G. T. C. Ko, F. K. L. Chan, W.-B. Chan et al., "*Helicobacter pylori* infection in chinese subjects with type 2 diabetes," *Endocrine Research*, vol. 27, no. 1-2, pp. 171–177, 2001.
- [15] Ö. Tanriverdi, "Association of *Helicobacter pylori* infection with microalbuminuria in type 2 diabetic patients," *Turkish Journal of Gastroenterology*, vol. 22, no. 6, pp. 569–574, 2011.
- [16] T. Senmaru, M. Fukui, M. Kuroda et al., "Serum pepsinogen I/II ratio is correlated with albuminuria in patients with type 2 diabetes," *Endocrine Journal*, vol. 60, pp. 161–166, 2013.
- [17] D. A. de Luis, M. Lahera, R. Cantón et al., "Association of *Helicobacter pylori* infection with cardiovascular and cerebrovascular disease in diabetic patients," *Diabetes Care*, vol. 21, no. 7, pp. 1129–1132, 1998.
- [18] S. A. Hamed, N. F. Amine, G. M. Galal et al., "Vascular risks and complications in diabetes mellitus: the role of *Helicobacter pylori* infection," *Journal of Stroke and Cerebrovascular Diseases*, vol. 17, no. 2, pp. 86–94, 2008.
- [19] M. Candelli, D. Rigante, G. Marietti et al., "*Helicobacter pylori*, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients," *Pediatrics*, vol. 111, no. 4, pp. 800–803, 2003.
- [20] C. Colombo, P. A. Tomasi, G. F. Meloni, A. M. Marinaro, A. Ogana, and T. Meloni, "Seroprevalence of *Helicobacter pylori* in children with type 1 diabetes mellitus in Sardinia," *Diabetes, Nutrition and Metabolism—Clinical and Experimental*, vol. 15, no. 2, pp. 91–95, 2002.
- [21] R. E. Begue, A. Mirza, T. Compton, R. Gomez, and A. Vargas, "*Helicobacter pylori* infection and insulin requirement among children with type 1 diabetes mellitus," *Pediatrics*, vol. 103, no. 6, p. e83, 1999.
- [22] M. M. El-Eshmawy, A. K. El-Hawary, S. S. Abdel Gawad, and A. A. El-Baiomy, "*Helicobacter pylori* infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis," *Diabetology and Metabolic Syndrome*, vol. 3, no. 1, article 28, 2011.
- [23] D. Arslan, M. Kendirci, S. Kurtoglu, and M. Kula, "*Helicobacter pylori* infection in children with insulin dependent diabetes mellitus," *Journal of Pediatric Endocrinology and Metabolism*, vol. 13, no. 5, pp. 553–556, 2000.
- [24] J. Vafaeimanesh, A. Heidari, M. Effatpanah, and M. Parham, "Serum adiponectin level in diabetic patients with and without *Helicobacter pylori* infection: is there any difference?" *The Scientific World Journal*, vol. 2014, Article ID 402685, 4 pages, 2014.
- [25] K. E. Wellen and G. S. Hotamisligil, "Inflammation, stress, and diabetes," *Journal of Clinical Investigation*, vol. 115, no. 5, pp. 1111–1119, 2005.
- [26] M. Diomed, P. Stanzione, F. Sallustio et al., "Cytotoxin-associated gene-A—positive *Helicobacter pylori* strains infection increases the risk of recurrent atherosclerotic stroke," *Helicobacter*, vol. 13, no. 6, pp. 525–531, 2008.
- [27] M. Candelli, D. Rigante, G. Marietti et al., "*Helicobacter pylori* eradication rate and glycemic control in young patients with type 1 diabetes," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 38, no. 4, pp. 422–425, 2004.
- [28] M. Akanuma, A. Yanai, K. Sakamoto et al., "Influence of *Helicobacter pylori* eradication on the management of type 2 diabetes," *Hepato-Gastroenterology*, vol. 59, no. 114, pp. 641–645, 2012.
- [29] W. Yoshiharu, Y. Hamamoto, Y. Kawasaki et al., "The eradication of *Helicobacter pylori* does not affect glycemic control in Japanese subjects with type 2 diabetes," *Journal of Japanese Clinical Medicine*, vol. 4, pp. 41–43, 2013.

- [30] D. A. de Luis, J. M. Cordero, C. Caballero et al., "Effect of the treatment of *Helicobacter pylori* infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus," *Diabetes Research and Clinical Practice*, vol. 52, no. 1, pp. 1–9, 2001.
- [31] R. E. Bégué, R. Gómez, T. Compton, and A. Vargas, "Effect of *Helicobacter pylori* eradication in the glycemia of children with type 1 diabetes: a preliminary study," *Southern Medical Journal*, vol. 95, no. 8, pp. 842–845, 2002.